Miss Angela Casbard - CONVERIS Research Information System by Thomson Reuters: - Converis Standard Config

Go to Header Go to Navigation Go to Content Go to Footer

List of persons » Miss Angela Casbard

Miss Angela Casbard

Projects as PI

Go to first page

Go to previous page

1 of 2

Go to next page

Go to last page

A phase 1b/randomised placebo controlled phase II trial of fulvestrant +/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor - FAKTION CRUK - Funder:Cancer Research UK (01/10/2013 - 31/10/2019)

A randomised double blind placebo controlled phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy - FURVA AZ - Funder:AstraZeneca UK Ltd (01/10/2014 - 31/12/2021)

A randomised double blind placebo controlled phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy - FURVA CRUK - Funder:Cancer Research UK (01/10/2014 - 30/09/2017)

A randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma - VIM - Funder:Cancer Research UK, - Funder:University of Leicester (01/11/2013 - 31/12/2021)

Evaluation of the safety of CEdiranib in the prevention of bowel perforation in platinum-resistant Ovarian Cancer (CEBOC) - Funder:AstraZeneca UK Ltd (30/11/2017 - 31/08/2022)

Projects as Co-Investigator

Go to first page

Go to previous page

1 of 2

Go to next page

Go to last page

A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective length of anticoagulation with low molecular weight heparin in the treatment of Cancer Associated Thrombosis (ALICAT) - Funder:National Institute for Health Research (01/03/2013 - 28/02/2015)

A phase I/II trial of the mTOR inhibitor temsirolimus (CCI-779; torisel) plus gemcitabine and cisplatin as first-line therapy for metastatic bladder cancer (and other urothelial cell carcinomas) (TOTEM) - Funder:Cancer Research UK (01/02/2008 - 31/12/2015)

A randomised phase II trial of carboplation and gemcitabane +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin - TOUCAN - Funder:AstraZeneca UK Ltd, - Funder:AstraZeneca UK Ltd (19/10/2009 - 30/09/2020)

Centre for trials research cancer group: Core funding QQR CTR and Haematology Clinical Trials Unit - Funder:Cancer Research UK (01/10/2018 - 30/09/2023)

Clinical trial fellow in association with The Centre for Trials Research - Funder:Cancer Research UK (01/06/2019 - 30/11/2021)

Last updated on 2021-01-03 at 22:04